We are live on ! Find out more
VEA

Virtus ETF Advisers Portfolio holdings

AUM $215M
1-Year Est. Return 53.68%
This Fund
S&P 500
This Quarter Est. Return
+9.34%
1 Year Est. Return
+53.68%
3 Year Est. Return
+121.72%
5 Year Est. Return
+144.54%
10 Year Est. Return
+633.35%
AUM
$612M
AUM Growth
+$115M
Cap. Flow
+$88.3M
Cap. Flow %
14.44%
Top 10 Hldgs %
8.98%
Holding
532
New
97
Increased
238
Reduced
88
Closed
80

Top Buys

Rank Stock Value
1
TEO icon
Telecom Argentina
TEO
+$2.03M
2
MEOH icon
Methanex
MEOH
+$1.43M
3
EQM
EQM Midstream Partners, LP
EQM
+$1.32M
4
CGBD icon
Carlyle Secured Lending
CGBD
+$1.31M
5
GEO icon
The GEO Group
GEO
+$1.3M

Top Sells

Rank Stock Value
1
OXSQ icon
Oxford Square Capital
OXSQ
+$2.73M
2
MPLX icon
MPLX
MPLX
+$1.51M
3
MDCO
Medicines Co
MDCO
+$982K
4
GAIN icon
Gladstone Investment Corp
GAIN
+$857K
5
CELG
Celgene Corp
CELG
+$712K

Sector Composition

Rank Sector Weight
1 Financials 20.46%
2 Real Estate 16.88%
3 Energy 14.34%
4 Healthcare 10.85%
5 Materials 9.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CCXI
201
DELISTED
ChemoCentryx, Inc.
CCXI
$519K 0.08%
13,115
-17,171
-57% -$302K
CLVS
202
DELISTED
Clovis Oncology, Inc.
CLVS
$517K 0.08%
49,615
-3,890
-7% -$28.3K
ASND icon
203
Ascendis Pharma A/S
ASND
$16.7B
$497K 0.08%
3,569
+1,471
+70% +$163K
ESPR
204
DELISTED
Esperion Therapeutics
ESPR
$495K 0.08%
8,298
+3,154
+61% +$142K
CNST
205
DELISTED
Constellation Pharmaceuticals, Inc.
CNST
$493K 0.08%
+10,465
New +$302K
CVM icon
206
CEL-SCI Corp
CVM
$20.6M
$487K 0.08%
+1,774
New +$418K
BCRX icon
207
BioCryst Pharmaceuticals
BCRX
$2.37B
$479K 0.08%
138,719
+64,186
+86% +$161K
CTMX icon
208
CytomX Therapeutics
CTMX
$705M
$478K 0.08%
57,537
+33,236
+137% +$224K
KRTX
209
DELISTED
Karuna Therapeutics, Inc. Common Stock
KRTX
$475K 0.08%
+6,306
New +$276K
MRTX
210
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$474K 0.08%
3,678
+988
+37% +$95.3K
KOD icon
211
Kodiak Sciences
KOD
$2.59B
$468K 0.08%
+6,501
New +$237K
TPTX
212
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
$464K 0.08%
+7,444
New +$354K
ODT
213
DELISTED
Odonate Therapeutics, Inc. Common Stock
ODT
$462K 0.08%
+14,229
New +$441K
ORTX
214
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$459K 0.08%
3,337
+1,600
+92% +$195K
APLS
215
DELISTED
Apellis Pharmaceuticals
APLS
$456K 0.07%
14,888
+2,953
+25% +$81.7K
TGTX icon
216
TG Therapeutics
TGTX
$8.58B
$453K 0.07%
40,789
+5,986
+17% +$45.5K
PRNB
217
DELISTED
Principia Biopharma Inc. Common Stock
PRNB
$453K 0.07%
8,277
+983
+13% +$36.7K
FTSV
218
DELISTED
Forty Seven, Inc. Common Stock
FTSV
$453K 0.07%
11,517
-12,462
-52% -$200K
ADVM
219
DELISTED
Adverum Biotechnologies
ADVM
$450K 0.07%
3,908
+1,573
+67% +$139K
MYOK
220
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$450K 0.07%
6,174
+687
+13% +$41.7K
NXTC icon
221
NextCure
NXTC
$17.3M
$447K 0.07%
+661
New +$332K
CRBP icon
222
Corbus Pharmaceuticals
CRBP
$170M
$446K 0.07%
2,725
+1,496
+122% +$221K
ZYME icon
223
Zymeworks
ZYME
$1.68B
$446K 0.07%
+9,809
New +$356K
BPMC
224
DELISTED
Blueprint Medicines
BPMC
$444K 0.07%
5,540
+2,744
+98% +$205K
ARDX icon
225
Ardelyx
ARDX
$1.24B
$442K 0.07%
+58,852
New +$358K
7 8
9
10 11

Similar funds

NCM
NEXTBio Capital Management Menlo Park, California $215M AUM
SSA
SSA Swiss Advisors Zurich $216M AUM 17.86% 1-Year Est. Return
LIWM
Long Island Wealth Management Melville, New York $216M AUM 14.59% 1-Year Est. Return
VFG
V2 Financial group Naperville, Illinois $215M AUM 15.18% 1-Year Est. Return
IAM
Impala Asset Management Palm Beach, Florida $215M AUM 86.77% 1-Year Est. Return
1M
1248 Management Kansas City, Missouri $216M AUM 12.29% 1-Year Est. Return
GC
GatePass Capital Independence, Ohio $214M AUM 29.83% 1-Year Est. Return
ALS
Andrew L. Share $214M AUM 14.75% 1-Year Est. Return

Virtus ETF Advisers's Q4 2019 Portfolio in Review

As of Q4 2019, Virtus ETF Advisers held 532 positions worth $612M, up 23% from $496M the previous quarter. Its ten largest holdings account for 9% of the portfolio.

Virtus ETF Advisers deployed $88.3M of net new capital in Q4 2019, opening 97 new positions and adding to 238 existing holdings. Its largest new stake was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.

By sector, the portfolio is most concentrated in Financials at 20% of assets, down from 24% a quarter earlier, followed by Real Estate and Energy.

On the sell side, the largest reduction was Oxford Square Capital, an estimated $2.73M trimmed.

  • Virtus ETF Advisers's largest Q4 2019 buy was Odonate Therapeutics, Inc. Common Stock: 14,229 shares worth $462K.
  • Virtus ETF Advisers added most to Telecom Argentina in Q4 2019, an estimated $2.03M increase.
  • Virtus ETF Advisers's biggest Q4 2019 reduction was Oxford Square Capital, cutting an estimated $2.73M.
  • Virtus ETF Advisers fully exited Medicines Co in Q4 2019, selling an estimated $982K.
  • Virtus ETF Advisers's ten largest holdings make up 9% of its $612M portfolio in Q4 2019.
  • Virtus ETF Advisers opened 97 new positions and closed 80 in Q4 2019.
  • Virtus ETF Advisers's portfolio value rose 23% quarter-over-quarter to $612M.

Based on Virtus ETF Advisers's 13F filing for Q4 2019, filed 13 Feb 2020.